عنوان
پدید آورنده
موضوع
رده
RC280.L9
RC280
.
L9
کتابخانه
محل استقرار
3319751840
9783319751849
3319751832
9783319751832
Resistance of targeted therapies excluding antibodies for lymphomas /
[Book]
Andrés J.M. Ferreri, editor.
Cham, Switzerland :
Springer,
2018.
1 online resource (xiii, 138 pages) :
illustrations (some color)
Resistance to targeted anti-cancer therapeutics,
volume 17
2196-5501 ;
Includes index.
Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Series Editor Biography; Acknowledgements; Editor's Biography; Preface; Contents; BTK Inhibitors: Focus on Ibrutinib and Similar Agents; Introduction; Ibrutinib Biochemical Structure, PK, PD, Routes and Doses; Ibrutinib: Efficacy and Safety Clinical Data; Resistance to BTK Inhibitors; Clinical Studies on Resistance Mechanisms in CLL; Prognosis After Disease Progression and Transformation in CLL; Resistance Mechanisms in MCL; Clinical Trials and Resistance Mechanisms in Waldenström's Macroglobulinemia.
Genetic and Functional HeterogeneityAlternative Proliferation Pathways; Molecular Mechanisms of mTOR Activation in Lymphomas; Summary of Clinical Trials; Temsirolimus; Everolimus; Ridaforolimus; Second Generation mTOR Inhibitors; Summary; References; Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents; The JAK/STAT Intracellular Signaling Pathway; Deregulated JAK/STAT Signaling in Lymphomagenesis; Mutations that Alter JAK2 Copy Number but Not Its Coding Sequence; Mutations that Directly Alter the JAK Family Members; Mutations that Target the STAT Family Members.
Other BTK InhibitorsConclusion; References; BCL2 Inhibitors: Insights into Resistance; Introduction; BCL2 and Cancer; BH3 Mimetics; ABT-737; Navitoclax; Venetoclax; Biochemistry; Pre-clinical Data; Administration and Pharmacokinetics; Clinical Outcomes; Clinical Effect of Resistance; Molecular Mechanisms of Resistance; Conclusion; References; Proteasome Inhibitors with a Focus on Bortezomib; Introduction; The Ubiquitin Proteasome System; Proteasome Inhibitors: Mechanism of Anti-tumor Effect; Cell Intrinsic Mechanisms of Resistance; Proteasome Subunit Mutations; Efflux Pumps; Autophagy.
Plasmacytic DifferentiationProteasome Subunit Expression; BCL-2; Cell Extrinsic Mechanisms of Resistance; Interleukin-6; The Hedgehog Pathway; Overcoming Bortezomib Resistance; Targeting the Immature Plasma Cell; Differentiation Induction; Synergistically Activating the Unfolded Protein Response; BCL-2 Inhibition; Conclusion; References; IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms; Introduction; Non-Hodgkin's Lymphoma; Lenalidomide for the Treatment of Lymphoma.
Structure and Mechanism of ActionToxicities; Other Insights from Preclinical Models; Clinical Indications and Data; Predictive Markers for Lenalidomide in Patients with Lymphoma; Molecular Mechanisms of Resistance; Future Directions; References; mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents; Introduction: Rapamycin and Rapalogs History; The mTOR Pathway and mTOR Inhibitors; Pharmacokinetics of Rapalogs; Toxicity; Pneumonitis; Metabolic Adverse Events; Hematological Toxicities; mTOR Inhibitors Associated Stomatitis (mIAS); Mechanisms of Resistance; Mutations of mTOR.
0
8
8
8
8
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
Springer Nature
com.springer.onix.9783319751849
Resistance of targeted therapies excluding antibodies for lymphomas.
9783319751832
Drug targeting.
Lymphomas-- Chemotherapy.
Drug targeting.
HEALTH & FITNESS-- Diseases-- General.
Lymphomas-- Chemotherapy.
MEDICAL-- Clinical Medicine.
MEDICAL-- Diseases.
MEDICAL-- Evidence-Based Medicine.
MEDICAL-- Internal Medicine.
Medical research.
Oncology.
HEA-- 039000
MED-- 014000
MED-- 022000
MED-- 045000
MED-- 112000
MJCL
616
.
99/446061
23
RC280
.
L9
Ferreri, Andrés J. M.
20200823105637.0
pn
مطالعه متن کتاب [Book]
Y
